-
Electronic (PDF)
-
Site License
-
Enterprisewide
APT Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011
Global Markets Direct, March 2011, Pages: 31
APT Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011
Summary
Global Market Direct’s pharmaceuticals report, “APT Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- APT Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of APT Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of APT Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the APT Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate APT Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of APT Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the APT Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with APT Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of APT Pharmaceuticals, Inc. and identify potential opportunities in those areas.
List of Tables
List of Figures
APT Pharmaceuticals, Inc. Snapshot
APT Pharmaceuticals, Inc. Overview
Key Information
Key Facts
APT Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
APT Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
APT Pharmaceuticals, Inc. – Pipeline Products Glance
APT Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
APT Pharmaceuticals, Inc. – Drug Profiles
Inhaled Anti-Inflammatory Agent
Product Description
Mechanism of Action
R&D Progress
APT Pharmaceuticals, Inc. – Pipeline Analysis
APT Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
APT Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
APT Pharmaceuticals, Inc. - Dormant Projects
APT Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Mar 23, 2006: Aradigm And APT Pharmaceuticals Initiates Phase 2 Clinical Program Of Novel Treatment For Asthma
Jul 21, 2005: Aradigm Corporation (ARDM) And APT Pharmaceutical LLC Announces Progression Of AERx HCQ Program Into Phase 2 Clinical Trials
Jul 21, 2005: Aradigm Corporation (ARDM) And APT Pharmaceutical LLC Announces Progression Of AERx HCQ Program Into Phase 2 Clinical Trials
Jul 15, 2005: FDA Requests Additional Data On PULMINIQ Inhalation Solution
Jun 07, 2005: Chiron Expects FDA Decision On New Therapy For Lung-Transplant Patients
Nov 19, 2004: APT Completes Phase I Studies With Aerosolized Hydroxychloroquine For Asthma
Oct 14, 2004: Chiron Submits New Drug Application For PULMINIQ
Sep 13, 2004: APT Starts Human Trials Of Aerosolized Hydroxychloroquine For Asthma.
Jun 17, 2003: APT Patents Targeted Delivery Of Hydroxychloroquine For Inflammatory Diseases
Financial Deals Landscape
APT Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2011
APT Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2011
APT Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
APT Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
APT Pharmaceuticals Secures $32.3 Million In Series B Financing
APT Pharmaceuticals Secures $22 Million In Series A-2 Round Of Funding
APT Pharmaceuticals Secures $9 Million In Series A Round Of Financing
Licensing Agreements
APT Pharmaceuticals Enters Into Licensing Agreement With Novartis Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
APT Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
APT Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
APT Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
APT Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2011
APT Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2011
APT Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
APT Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
APT Pharmaceuticals, Inc., Deals Summary by Region, 2004 to YTD 2011
APT Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
List of Figures
APT Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
APT Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
APT Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
APT Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
